FKAdam,

I would have your friends and colleagues read the talk market piece from last night. It does a good job of explaining both the HIV and covid regulatory situations for leronlimab.

https://talkmarkets.com/content/stocks--equit...ost=284999

I imagine at this point that your doubting colleagues are bailing due to share price pummeling in the face of remdesivir, Pfizer vaccine and the Lilly mAb.

A deep dive into science is unlikely to ease frayed nerves.